Summary & Overview
CPT 80338: Antidepressant Detection and Quantitation Assay
CPT code 80338 represents a clinical laboratory assay used to detect or quantify antidepressant medications in patient specimens when no more specific CPT code applies. This test supports psychiatric medication monitoring, adherence assessment, therapeutic drug monitoring, and toxicology screening, and is relevant across outpatient clinics, inpatient hospitals, and independent laboratories nationwide. Coverage and reimbursement for 80338 affect diagnostic workflows, formulary management, and laboratory billing practices for patients receiving antidepressant therapy.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of how 80338 is used clinically, typical sites of service, common billing modifiers, and which payers are commonly involved in coverage decisions. The publication summarizes national relevance for behavioral health management and laboratory services, outlines operational considerations for labs and providers, and points to areas where policy updates or payer guidance can influence claims processing and medical necessity determinations.
Data not available in the input for associated taxonomies, specific ICD-10 diagnoses, and related codes is noted where applicable. The content is intended to inform billing staff, lab managers, compliance officers, and policy analysts about the clinical and administrative context of CPT code 80338.
Billing Code Overview
CPT code 80338 describes laboratory testing in which a lab analyst measures the amount of, or detects the presence of, antidepressant medications in a patient specimen. The code applies when the specific antidepressant or panel being tested is not otherwise specified by other CPT codes.
Service Type: Clinical laboratory drug assay / toxicology testing
Typical Site of Service: Clinical laboratory, hospital laboratory, or other certified diagnostic facility
Clinical & Coding Specifications
Clinical Context
A 35-year-old patient treated for major depressive disorder presents for a routine medication monitoring visit after a change in antidepressant therapy. The clinician orders a urine or serum toxicology assay to measure presence and/or concentration of antidepressant medications to confirm adherence, evaluate possible drug interactions, or assess suspected toxicity. The specimen is collected in an outpatient laboratory or hospital phlebotomy area and sent to the clinical chemistry/toxicology lab. The laboratory analyst performs qualitative or quantitative testing using immunoassay screening followed by confirmatory methods (eg, GC-MS or LC-MS/MS) if needed. Results are reported to the ordering psychiatrist or primary care provider, who documents interpretation in the medical record and adjusts therapy as clinically indicated. Typical sites of service include outpatient hospital laboratories, independent clinical laboratories, and ambulatory clinic laboratories.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Default billing modifier indicating no special circumstances | Used when no other modifier applies and standard lab processing/reporting occurred |
22 | Increased procedural services | Use when work or resources for testing were significantly greater than usual (rare for fixed lab assays) |
26 | Professional component | Use when billing only the professional interpretation/reporting component separate from technical laboratory processing |
52 | Reduced services | Use when specimen or testing was partially completed resulting in reduced service |
53 | Discontinued procedure | Use when testing was started but discontinued for patient-related reasons prior to completion |
62 | Two surgeons/dual physician involvement | Rare; use when two qualified physicians share responsibility for interpretation/reporting of complex toxicology analysis |
78 | Unplanned return to the operating/procedure room by the same physician following initial procedure | Not commonly used for lab testing; included when same-day unplanned procedures necessitate additional testing by same provider |
80 | Assistant surgeon | Rare for laboratory tests; use if an assistant provider performed a billable portion of specimen collection under specific payer rules |
90 | Reference laboratory | Use when the service was performed by a CLIA-certified outside/reference laboratory and reporting is by that lab |
TC | Technical component | Use when billing only the technical component (instrumentation, reagents, personnel) separate from professional interpretation |
QX | Modifier for certified nurse midwife, nurse practitioner, or physician assistant services under certain billing arrangements | Use when applicable provider qualifications require modifier reporting for the service |
QY | Clinic/office or other authorizing entity when provider is working under a clinical laboratory improvement program exemption | Use when applicable under payer-specific rules |
AS | Physician assistant, nurse practitioner, or clinical nurse specialist services in lieu of physician | Use per payer policy when advanced practice provider furnished the service |
| Taxonomy Code | Specialty | Notes |
|---|---|---|
2084P0800X | Psychiatry & Neurology | Psychiatrists commonly order and interpret antidepressant testing for therapeutic monitoring |
208D00000X | Clinical Pathology | Laboratory pathologists oversee toxicology testing methods and quality control |
363L00000X | Clinical Laboratory | Clinical laboratory directors and analysts perform the assay and reporting |
208000000X | Family Medicine | Primary care physicians frequently order antidepressant level or presence testing for medication management |
208000000X | Internal Medicine | Internists manage chronic antidepressant therapy and may request objective laboratory confirmation |
Related Diagnoses
| ICD-10 Code | Description | Clinical Relevance |
|---|---|---|
F32.1 | Major depressive disorder, single episode, moderate | Antidepressant presence testing is relevant to monitor adherence and treatment response |
F33.1 | Major depressive disorder, recurrent, moderate | Used for ongoing therapeutic drug monitoring when recurrent depression requires medication management |
F41.1 | Generalized anxiety disorder | Antidepressants frequently prescribed for anxiety disorders; testing may assess adherence or interactions |
F43.21 | Adjustment disorder with depressed mood | Short-term antidepressant treatment monitoring may include presence testing |
T42.4X5A | Poisoning by selective serotonin reuptake inhibitors, accidental (initial encounter) | Relevant when assessing suspected toxicity or overdose of antidepressant agents |
Related CPT Codes
| CPT Code | Description | Relationship to This Procedure |
|---|---|---|
80307 | Drug screen, presumptive, any number of drug classes; non-automated, per date of service | Commonly used as an initial immunoassay screen for multiple drug classes prior to specific antidepressant testing |
80305 | Drug screen, presumptive, any number of drug classes; presumptive, by instrumented method, qualitative | Instrumented presumptive drug testing often performed before or alongside antidepressant-specific assays |
80339 | Antidepressant assay, specific drug, quantitative | Used when quantitative measurement of a specific antidepressant is required; complements 80338 when the specific agent is identified |
82570 | Drug assay, amphetamine and metabolites; qualitative | Other toxicology assays commonly performed in psychiatric patients to evaluate co-occurring substance use alongside antidepressant testing |
82542 | Drug assay, benzodiazepine; definitive, quantitative | Definitive confirmatory testing for sedative-hypnotics that may interact with antidepressants; often performed in the same toxicology panel |
81003 | Urinalysis, automated, non-microscopic; with reflex microscopic exam | Specimen evaluation performed concurrently to assess urine integrity and potential contamination for urine-based antidepressant testing |